NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Nemaura Medical, Inc., a Nevada corporation (the “Company”) issued a press release (the “Press Release”) on March 3, 2020. A copy of the Press Release is attached as Exhibit 99.1 hereto. The information included in the Press Release shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release of the registrant. |
Nemaura Medical Inc. Exhibit
EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 Nemaura Medical Launches sugarBEATÒ App on Play Store Ahead of its Planned Commercial Launch of BEATÒdiabetes Subscription Service sugarBEAT® App is now available on Play Store with iOS app planned to follow,…
To view the full exhibit click here
About NEMAURA MEDICAL, INC. (OTCMKTS:NMRD)
Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.
